We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Alkermes Hit With Complete Response Letter Over Schizophrenia, Bipolar Disorder Drug Candidate
Alkermes Hit With Complete Response Letter Over Schizophrenia, Bipolar Disorder Drug Candidate
Alkermes was slapped with a Complete Response Letter from the FDA regarding its new drug application (NDA) for ALKS 3831 (olanzapine/samidorphan) for the treatment of adults with schizophrenia and adults with bipolar I disorder.